IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor-Reference-Cited by-同舟云学术

IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor

Published:2019-03-12 Issue:7 Volume:5 Page:1045-1051
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Reck Folkert¹^ORCID,Bermingham Alun¹,Blais Johanne¹,Casarez Anthony¹,Colvin Richard²,Dean Charles R.¹^ORCID,Furegati Markus³,Gamboa Luis¹,Growcott Ellena¹,Li Cindy¹,Lopez Sara¹,Metzger Louis¹,Nocito Sandro³,Ossola Flavio³,Phizackerley Kaci¹,Rasper Dita¹,Shaul Jacob¹,Shen Xiaoyu¹,Simmons Robert L.¹,Tang Dazhi¹,Tashiro Kyuto¹,Yue Qin¹

Affiliation:

1. Novartis Institutes for BioMedical Research, 5300 Chiron Way, Emeryville, California 94608, United States

2. Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

3. Synthesis and Technologies Group, Novartis Institutes for BioMedical Research, Klybeckstrasse 141, Basel 4057, Switzerland

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Link

http://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.9b00031

Reference46 articles.

1. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data

2. Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria

3. Carbapenemase-Producing Organisms: A Global Scourge

4. Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae – Identification of LYS228

5. Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approachable Synthetic Methodologies for Second-Generation β-Lactamase Inhibitors: A Review;Pharmaceuticals;2024-08-23

2. Ionizable Lipid Containing Nanocarriers for Antimicrobial Agent Delivery;Small Science;2024-08-13

3. Synthesis of novel ciprofloxacin-avibactam conjugates for the development of second-generation non-β-lactam-β-lactamase inhibitors;Bioorganic & Medicinal Chemistry Letters;2023-05

4. Recent advances in β-lactamase inhibitor chemotypes and inhibition modes;European Journal of Medicinal Chemistry;2022-11

5. Inhibition Mechanism of Class D β-Lactamases by Avibactam;ACS Catalysis;2022-08-08